LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_001003841.3:c.517G>A
SLC6A19
· NP_001003841.1:p.(Asp173Asn)
· NM_001003841.3
GRCh37: chr5:1212453 G>A
·
GRCh38: chr5:1212338 G>A
Gene:
SLC6A19
Transcript:
NM_001003841.3
Final call
VUS
PS3 supporting
BP4 moderate
Variant details
Gene
SLC6A19
Transcript
NM_001003841.3
Protein
NP_001003841.1:p.(Asp173Asn)
gnomAD AF
0.003103546148516582 (v4.1)
ClinVar
Pathogenic
OncoKB
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PS3 supporting: D173N showed reduced or altered B0AT1 transport and surface expression in orthogonal oocyte assays.
2
BP4 moderate: REVEL 0.179 meets the generic missense threshold for BP4 moderate.
Final determination:
Under the generic ACMG/AMP 2015 fallback, the applied PS3 supporting and BP4 moderate criteria satisfy neither a pathogenic nor a benign combination, so the call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PS1 | Not assessed | Not assessed: D173N is reported, but no pathogenic alternate-nucleotide change producing the same Asp173Asn substitution is documented. |
clinvar
PMID:17555458
|
| PS2 | Not assessed | Not assessed: no documented affected proband with confirmed maternity and paternity, parental genotypes, and absent family history is available. |
|
| PS3 | Met | Met at supporting: D173N showed relatively low amino-acid transport in oocytes compared with wild type, with orthogonal assays demonstrating altered transport and surface expression. |
PMID:19185582
|
| PS4 | Not assessed | Not assessed: D173N is reported in Hartnup families, but no verifiable matched control count, OR/RR, or 95% CI is available for the >5.0 PS4 requirement. |
PMID:17555458
gnomad_v2
gnomad_v4
|
| PM1 | Not assessed | Not assessed: no approved domain or hotspot evidence places residue 173 in a critical region without benign variation. |
hotspots
|
| PM2 | Not met | Not met: gnomAD v4.1 AF is 0.00310355, above the <=0.0001 PM2 threshold, with 12 homozygotes observed. |
gnomad_v4
gnomad_v2
|
| PM3 | Not assessed | Not assessed: no affected-proband observation with a pathogenic variant confirmed in trans by parental or offspring phase testing is documented. |
PMID:17555458
PMID:18484095
|
| PM4 | N/A | Not applicable: PM4 requires a protein-length change, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PM5 | Not assessed | Not assessed: no confirmed pathogenic alternate missense substitution at residue 173 is documented; the known D173N reports are the target change itself. |
pm5_candidates
PMID:17555458
|
| PM6 | Not assessed | Not assessed: no affected-patient de novo observation is documented, even without parental maternity and paternity confirmation. |
|
| PP1 | Not assessed | Not assessed: papers mention D173N in unrelated families and recessive cosegregation, but provide no variant-specific affected-member genotypes or informative-meiosis count. |
PMID:17555458
PMID:18484095
|
| PP2 | Not assessed | Not assessed: the evidence lacks both a gene-level low-benign-missense measure and a systematic demonstration that missense is the common disease mechanism. |
PMID:17555458
PMID:19185582
|
| PP3 | Not met | Not met: REVEL 0.179 is below the generic PP3 supporting threshold of >=0.644 for missense variants. |
revel
|
| PP4 | Not assessed | Not assessed: Hartnup disorder is named, but no individual phenotype or family-history details establish the highly specific PP4 requirement. |
clinvar
PMID:15286788
|
| PP5 | Not met | Not met: ClinVar has 0 expert-panel submissions for the exact variant, so laboratory and aggregate pathogenic labels cannot trigger PP5. |
clinvar
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 0.00395819, below the 0.05 BA1 threshold, with 1,179,944 observed European non-Finnish alleles. |
gnomad_v4
gnomad_v2
|
| BS1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 0.00395819, below the generic 0.01 BS1 default, and the allele is a documented common recessive Hartnup disease allele. |
gnomad_v4
gnomad_v2
PMID:17555458
|
| BS2 | Not assessed | Not assessed: gnomAD v4.1 reports 12 homozygotes, but their adult health status, ages, phenotypes, and expected early full penetrance are not documented. |
gnomad_v4
|
| BS3 | Not met | Not met: D173N showed relatively low transporter activity and altered surface expression rather than demonstrating no damaging effect on protein function or splicing. |
PMID:19185582
|
| BS4 | Not assessed | Not assessed: no affected, variant-negative relatives or family-level non-segregation analysis is documented. |
|
| BP1 | Not met | Not met: recurrent disease-associated missense D173N and direct functional testing show that SLC6A19 disease is not established as primarily truncating. |
PMID:17555458
PMID:19185582
|
| BP2 | Not assessed | Not assessed: no documented cis or trans observation with a pathogenic variant and confirmed phase meets the BP2 definition. |
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| BP4 | Met | Met at moderate strength: REVEL 0.179 meets the generic BP4 moderate threshold of <=0.183 for missense variants. |
revel
|
| BP5 | Not assessed | Not assessed: no affected case with this variant and a confirmed alternate molecular diagnosis is documented. |
|
| BP6 | Not met | Not met: no exact-variant expert-panel benign or likely benign classification is present; available ClinVar submissions are non-expert assertions. |
clinvar
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous variant, and this is a missense variant. |
generic_acmg_combination_rules
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.